The World Celebrates Pfizer's 90% COVID-19 Vaccine Efficacy Data, With Cautious Caveats

Pfizer's vaccine for COVID-19 outpaced expectations on efficacy, driving a stock market rally and garnering reaction from Vice President Pence and President-elect Biden.

Hands clapping, applause
Positive COVID-19 vaccine data was applauded by investors and the public • Source: Shutterstock

Pfizer Inc. delivered the news the world was waiting for on 9 November, announcing its vaccine for COVID-19, developed with BioNTech SE, had a 90% efficacy rate in an interim analysis of an ongoing Phase III trial. The next step is waiting for the safety data, which could come next week and will inform a decision about regulatory filing.

At 90%, the initial efficacy rate is much higher than the 50% threshold the US Food and Drug Administration has...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Vaccines

More from Pink Sheet